BridgeBio Oncology Therapeutics, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, BridgeBio Oncology Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $2.85, 79.2% below its 52-week high and below its 200-day average, which is falling.

$2.85

+6.34% today

$228M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BBOT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-02-09 → 2026-10-22

S? 41w

S2 34w

S2 16w

S4 19w

2024-02-092026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S2 34w → S3 3w → S4 8w → S1 2w → S2 16w → S3 5w → S4 19w → S1 7w → S4 5w current

Total tracked: 141 weeks across 10 stage runs.

BBOT among Biotechnology443rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…443	BBOTBridgeBio Oncology Therapeutics, Inc.	Stage 4 · wk 5	14	−31.5%

vs 52W High

-79.2%

$2.68 lo$13.73 hi

79.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-66.2%

200 DMA: $8.43 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.18x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-31.5%

-67.7%

-68.2%

YTD

-76.8%

-74.1%

Scan Membership

Breakout Watch

Latest: 2024-11-22

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 1.18x

2026-10-21S4

Wk 5 · Vol 1.54x

2026-10-20S4

Wk 5 · Vol 1.23x

2026-10-19S4

Wk 5 · Vol 1.32x

2026-10-16S4

Wk 5 · Vol 0.92x

2026-10-15S4

Wk 4 · Vol 0.92x

2026-10-14S4

Wk 4 · Vol 0.85x

2026-10-13S4

Wk 4 · Vol 0.99x

2026-10-12S4

Wk 4 · Vol 0.46x

2026-10-09S4

Wk 4 · Vol 0.93x

2026-10-08S4

Wk 3 · Vol 1.12x

2026-10-07S4

Wk 3 · Vol 0.64x

Moving averages & range

50 DMA

$5.78

200 DMA

$8.43

52W High

$13.73

52W Low

$2.68

5D Low

$2.68

Resistance levels (recent highs)

20d High

$4.10

60d High

$9.60

120d High

$9.60

250d High

$13.73

Next resistance

+43.9%

to 20d High

ROE

-81.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

BridgeBio Oncology Therapeutics: quick answers

What stage is BridgeBio Oncology Therapeutics in?

As of Oct 22, 2026, BridgeBio Oncology Therapeutics (BBOT) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean

Is BridgeBio Oncology Therapeutics in an uptrend?

No. BridgeBio Oncology Therapeutics is in a Stage 4 downtrend. It trades 66.2% below its 200-day average, which is falling.

How far is BridgeBio Oncology Therapeutics from its 52-week high?

BridgeBio Oncology Therapeutics closed at $2.85 on Oct 22, 2026, 79.2% below its 52-week high of $13.73. Its 52-week low is $2.68.

How has BridgeBio Oncology Therapeutics performed over the past year?

As of Oct 22, 2026, BridgeBio Oncology Therapeutics is down 74.1% over the past year and down 76.8% so far in 2026.

Which sector and industry is BridgeBio Oncology Therapeutics in?

BridgeBio Oncology Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.